“The actions taken by your agency … directly contradict your testimony. I ask that you honor your statements and ensure that all FDA employees feel comfortable expressing their opinion, both inside the Agency and to Congress.”
The letter goes on to demand that the FDA respond to several queries by Feb. 17, including:
• Who authorized the monitoring of the whistleblowers;
• Which of them have departed the agency, and under what circumstances;
• Did email monitoring only target the whistleblowers;
• Is the agency currently monitoring any of its current employees;
• Whether the agency has reassured its employees that they are allowed to communicate with Congress; and
• Whether the agency has any procedures in place to ensure that congressional correspondence with agency employees remains confidential.